Status:
COMPLETED
Study of the Safety of Orencia in Japanese Children and Adolescents With Active Juvenile Arthritis of Unknown Origin
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Ono Pharmaceutical Co. Ltd
Conditions:
Undifferentiated Arthritis
Eligibility:
All Genders
Brief Summary
Observational study of abatacept in the treatment of JIA in Japan.
Eligibility Criteria
Inclusion
- All JIA participants who initiate treatment with Orencia in accordance with the prescribing information
Exclusion
- Participants receiving Orencia for an off-label indication
- Other protocol defined inclusion/exclusion criteria could apply
Key Trial Info
Start Date :
April 6 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 21 2021
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT03466814
Start Date
April 6 2018
End Date
July 21 2021
Last Update
June 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Shinjuku-ku, Tokyo, Japan, 162-0822